A method of covalently modifying tyrosines, tryptophans, and pyrrolated lysines in a protein comprising reacting the side chains of the amino acids with a cyclic imine Mannich electrophile appended to a ligand that binds to the protein; and a protein comprising a ligand binding site, which comprises one or more tyrosine, tryptophan or pyrrolated lysine residues, the side chains of which have been selectively covalently modified with a cyclic imine.
The invention generally relates to systems and methods for combined spectroscopy systems. In certain embodiments, laser-induced breakdown spectroscopy (LIBS) and Raman spectroscopy can be combined in a single, handheld device using a single spectrometer and two sources for simultaneous analysis using both methods.
G01J 3/30 - Measuring the intensity of spectral lines directly on the spectrum itself
H01J 49/16 - Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
3.
EXCIPIENT-FREE LYOPHILIZATION OF POLYMER LUNG SURFACTANTS
The present disclosure relates to a protocol for the formulation and lyophilization of hydroxyl-terminated poly(ethylene glycol) (PEG) based block copolymer micelles without the use of excipients (cryo-protectants). The micelles are formulated using the equilibrium nanoprecipitation (ENP) method, which allows for control over the aggregation number of the micelles and thus the grafting density of the PEG micelle corona chains. By using the ENP method to produce micelles with high dimensionless PEG grafting densities (> about 7), the micelles are stabilized against aggregation during lyophilization due to the shielding of the micelle core domains by the dense PEG corona chains. By preventing aggregation during the lyophilization without using excipients, the original desired surface mechanical properties of the micelles are preserved after reconstitution. Therefore, the protocol described herein can be applied to effectively storing PEG-based block copolymer micelles without using excipients while still preserving their original surface mechanical properties.
B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
An optical waveguide may include a core that is substantially transparent at an operating wavelength. The core may extend along a longitudinal direction. The optical waveguide may further include a cladding positioned on either side of the core. The cladding may include a plurality of layers, and each layer may extend along the longitudinal direction. At least one of the layers may include a plurality of elongated rods of a high index semiconductor. A gap may be defined between respective ends of the rods.
G02F 1/295 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the position or the direction of light beams, i.e. deflection in an optical waveguide structure
G02B 6/124 - Geodesic lenses or integrated gratings
5.
TEMPORALLY MULTI-STAGED BATCH COUNTERFLOW REVERSE OSMOSIS FOR HIGH RECOVERY DESALINATION
A temporally multi-staged assembly for reverse osmotically desalinating water is disclosed. Temporally multi-staged batch CFRO is realized by connecting each side of an RO membrane to one or more recirculation tanks. The side of the membrane that loses water is called the concentrate side while the other side gaining water is called the diluate side. In this embodiment a pressure exchanger design is used and hence the recirculation tanks are maintained at atmospheric pressure. Each stage operates in the same way as single-stage batch CFRO starting with the same concentrate and diluate salinity. The difference lies in the way the diluate is processed in each stage. For single-stage batch CFRO that dewaters seawater RO brine, the diluate produced is at seawater salinity and is used to increase the recover of the combined RO-CFRO s stem.
A61B 5/029 - Measuring blood output from the heart, e.g. minute volume
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
7.
METHODS FOR EMPLOYING MASS SPECTROMETRY TECHNIQUES TO SEQUENCE AND ANALYZE BIOLOGICAL MOLECULES
The invention generally relates to methods for employing mass spectrometry techniques to sequence and analyze biological molecules, such as glycan. In certain aspects, the invention provides methods for sequencing a biological molecule that involve conducting two-dimensional tandem mass spectrometry (2D MS/MS) and in-source collision-induced dissociation (IS-CID) on an ionized biological molecule to generate and analyze a plurality of precursor-product ion pairs of the biological molecule to thereby determine an interrelationship of the plurality of precursor-product ion pairs and sequence the biological molecule.
For each avatar, testing images are rendered for different facial expressions that each have ground truth facial action units. An instance of a machine learning model is applied to the testing images to generate predicted facial action units for each testing image. A predictive performance of the instance is calculated for each avatar based on the predicted and ground truth facial action units for the testing images of the avatar. A first set of features common to the avatars for which the predictive performance was better than a first threshold, and a second set of features common to the avatars for which the predictive performance was worse than a second threshold, are identified. The features present only in the second set are identified, as difference features. New avatars having the difference features are generated.
G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
G06V 20/20 - Scenes; Scene-specific elements in augmented reality scenes
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components
G06N 3/04 - Architecture, e.g. interconnection topology
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventor
Hu, Chang-Deng
Asberry, Andrew, M.
Cai, Xinpei
Deng, Xuehong
Sims, Hunter
Camacho, Carlos, J.
Dai, Mingji
Abstract
Disclosed are inhibitors of a protein-protein interaction between protein arginine methyltransferase 5 (PRMT5) and methylosome protein 50 (MEP50) based on isoxazolyl methoxyphenyl derivatives. Further disclosed are pharmaceutical compositions comprising PRMT5:MEP50 inhibitors and methods of inhibiting protein arginine methyltransferase 5 (PRMT5) using PRMT5.MEP50 inhibitors or pharmaceutical compositions comprising PRMT5:MEP50 inhibitors.
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 215/04 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
10.
UNIVERSAL NATURAL KILLER CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS AND METHOD OF USE
A population of universal natural killer (NK) cells derived from human pluripotent stem cells (hPSCs) and engineered to overexpress the transcription factor ID2, NFIL3, and/or SPI1 and, optionally, an anti-programmed death ligand 1 (PD-L1) chimeric antigen receptor (CAR) and an anti -fluorescein isothiocyanate CAR are provided. Methods of treating cancer in a subject using the population of universal NK cells are also provided.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
11.
MUSSEL-INSPIRED TISSUE ADHESIVES AND METHODS OF USE THEREOF
Bioinspired adhesives comprising a macromolecule such as zein and one or more catechol- or gallol-containing compounds are provided. The adhesive can also comprise an iron crosslinker, an interfacial crosslinker, or both an iron crosslinker and an interfacial crosslinker. Methods of manufacturing and using the adhesive are also provided.
The invention generally provides systems and methods for performing vessel segmentation from flow data, such as but not limited to 4D flow Magnetic Resonance Imaging (MRI) data. In certain aspects, the systems and methods of the invention may involve receiving flow data representative of flow in a vessel (such as 4D MRI flow data); identifying net flow effects in the flow data (such as 4D MRI flow data) according to a standardized difference of means (SDM) velocity that involves quantifying a ratio between net flow and observed flow pulsatility in each voxel of the received flow data (such as 4D MRI flow data); and identifying voxels with higher SDM velocity values than stationary tissue voxels, thereby performing vessel segmentation from flow data (such as 4D MRI flow data).
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
Methods for facilitating the genesis of photoreceptor rods in a subject by administering a therapeutically effective amount of a therapeutic agent are provided. Other methods are provided for treating retinitis pigmentosa by administering a therapeutically effective dose of therapeutic agents. Methods for producing an in vitro population of progenitor cells and photoreceptor rods generated therefrom are also provided.
A method for synthesis of Lorazepam in a continuous flow using continuous flow reactor, in which method comprises five steps including N-acylation, diazepine ring closure, imine N- oxidation, Polonovski-type rearrangement, and ester hydrolysis; a green reagent comprising a peroxide reagent and rhenium oxide catalyst for N-oxidation of delorazepam; and an ammonium source combination for the synthesis of delorazepam.
in plantain planta in planta includes co- incubating, post-anthesis, a cereal inflorescence of developing embryos with an inoculation medium comprising a transgene-modified Agrobacterium; collecting, upon the cereal inflorescence reaching maturity, seeds produced from at least a portion of the developing embryos; and selecting one or more transgenic seeds from among the collected seeds.
Platinum-thioester complexes, compositions comprising such platinum-thioester complexes, methods of treating cyanide poisoning and/or cyanide exposure with the same and related combinations therapies and kits therefore.
A conjugate comprising FL-L-IA, wherein FL is a radical of a ligand that specifically binds with fibroblast activation protein (FAP), L is a linker, which binds an FL to IA, and IA is a nanoparticle-based magnetic resonance imaging (MRI) agent; a composition comprising same; and a method of using the conjugate or composition to image cells, a tissue, or an organ that express(es) FAP.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07D 207/10 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (USA)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Edgar, Kevin J.
Petrova, Stella
Gao, Chengzhe
Taylor, Lynne
Abstract
Described in several exemplary embodiments herein are cellulose derivatives and amorphous solid dispersions thereof that can contain one or more agents, optionally one or more poorly soluble agents.
Chimeric antigen receptor (CAR)-expressing neutrophils loaded with nanoparticles comprising a drug; and a method of treating cancer or other disorders in a subject comprising administering to the subject a therapeutically effective amount of the CAR-expressing neutrophils.
A method of processing data by an imaging system is described. The imaging system generates a velocity data set and magnitude data set representative of a fluid. The method includes receiving velocity data set from the imaging system, calculating a phase variation data set from a wrapped phase field data set associated with the velocity data set, calculating a phase difference uncertainty data set from the magnitude data set, using the phase variation- data set and the phase difference uncertainty data set, performing a computational reconstruction of the phase field,data set to generate an unwrapped phase data set, converting the unwrapped phase to a first velocity field data set; and outputting a resultant velocity field set based upon the first velocity field data set.
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
22.
4-(3H-PYRAZOLO[4,3-F]QUINOLIN-7-YL)-N-(2-(DIMETHYLAMINO)ETHYL)BENZAMIDE- OR HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
N-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid derivative-comprising compounds for the inhibition of certain kinases for use in certain kinase-mediated disease states. Pharmaceutical compositions, conjugates, and methods for treating those kinase-mediated disease states are also provided.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
23.
COMBINATION OF SMALL MOLECULE DRUG CONJUGATE AND CAR-EXPRESSING CYTOTOXIC LYMPHOCYTES AND METHODS OF USE
A method of treating a cancer in a subject comprising administering to the subject (i) a small molecule drug conjugate (SMDC), which targets a cell-surface receptor on an immunosuppressive cell or a cancerous cell, and (ii) cytotoxic lymphocytes, which express a chimeric antigen receptor (CAR); and synergistic combinations of a SMDC and CAR-expressing cytotoxic lymphocytes.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Loop-mediated isothermal amplification assays, kits, and methods that target and/or detect the presence of a fecal indicator bacteria in a sample. These assays, kits, and methods can be portable and capable of providing fast (within 60 minutes) results in the field, eliminating the need for a laboratory and other complex equipment.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
A cohort corresponding to a wearer of a head-mountable display (HMD) is selected from a number of candidate cohorts that each correspond to a different facial type. A set of facial images of the wearer is captured using one or multiple cameras of the HMD. A machine learning model for the selected cohort is applied to the captured set of facial images to predict blendshape weights for the facial expression of the wearer exhibited within the captured set of images. Each candidate cohort has a differently trained machine learning model. The predicted blendshape weights for the facial expression of the wearer are retargeted onto an avatar corresponding to the wearer to render the avatar with the facial expression, and the rendered avatar is displayed.
A high-strength adhesive composition comprising components such as (i) an epoxidized oil, (ii) a nucleophile, and (iii) a phenolic compound derived from sustainably sourced, low-cost biological materials available on a large scale; its use; and a method of manufacturing.
Functionalized molecular layers comprising a backbone of polymerized amphiphiles for placement on a surface of a scaffold, such as a hydrogel. Methods of preparing such molecular layers and hydrogels comprising the same are also provided, as are methods of use thereof.
Described herein are new 8,9-dialoxy-7-azaindenoisoquinoline compounds (I), processes for their preparation, and methods of their use in the treatment of diseases responsive to inhibition of topoisomerase 1 and/or binding to the c-MYC G-Quadruplex.
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Label-free autofluorescence-detected photothermal mid-IR (AF-PTIR) microscopy is applied to test the distribution of materials within a sample. Two-photon excited UV-fluorescence (TPE-UVF) supports autofluorescence of native aromatic moieties using visible-light optics. Thermal modulation of the fluorescence quantum yield serves to report on infrared absorption, enabling infrared spectroscopy in the fingerprint region with a spatial resolution dictated by fluorescence. AF-PTIR provides high selectivity and sensitivity in image contrast for aromatic fluorescent materials, complementing broadly applicable optical photothermal IR (O-PTIR) microscopy based on photothermal modulation of refractive index/scattering. Mapping the fluorescent material distribution can be used to improve processes such as powdered dosage form manufacturing, with high spatial variance potentially producing variability in both delivered dosage and product efficacy. The ubiquity of aromatic moieties within active pharmaceutical ingredient candidates in particular suggests the viability of AF-PTIR in combination with O-PTIR to improve the confidence of chemical classification in spatially heterogeneous dosage forms.
G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
G01N 21/74 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light thermally excited using flameless atomising, e.g. graphite furnaces
G02B 21/16 - Microscopes adapted for ultraviolet illumination
A positively charged adhesive polymer comprising (i) a catechol-containing monomer, (ii) a filler monomer, and (iii) a cation-containing monomer, its use in dry and wet (e.g., damp, wet and underwater) adhesion, and its synthesis.
C09J 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
C09J 133/12 - Homopolymers or copolymers of methyl methacrylate
This disclosure describes systems, apparatuses, and techniques that use of multiple sensing modalities (multimodal sensing) in parallel to improve the detection, classification, and evaluation of seizures in subjects (e.g., mammalian subjects, such as humans). In some implementations, a wearable device includes a flex sensor configured, an inertial motion unit (IMU), and a plurality of surface electromyogram (sEMG) electrodes configured to be placed approximate to a muscle of a subject. The device also includes a microprocessor. The operations performed by the microprocessor include determining multimodal movement data of the muscle, where the multimodal movement data specifies at least an acceleration associated with movement of the muscle, an angular velocity associated with movement of the muscle, and sEMG activity associated with the movement of the muscle. The operation further includes determining whether the multimodal movement data indicates a possible seizure, and provide data based on the determination for output.
A61B 5/316 - Modalities, i.e. specific diagnostic methods
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
32.
METHODS OF PRODUCING CONSTRUCTION ELEMENTS, CONSTRUCTION ELEMENTS PRODUCED THEREBY, AND STRUCTURES PRODUCED THEREFROM
Processes for incorporating phase change materials (PCM) into porous construction elements, composite construction elements produced thereby, and structures constructed therefrom. Such a process includes heating a PCM to a temperature at or above a melting temperature thereof to liquify the PCM and yield a liquid PCM, fully immersing a porous construction element in the liquid PCM, and infiltrating the liquid PCM into porosity of the construction element while the construction element and liquid PCM are at a subatmospheric pressure level and at a temperature sufficient to maintain the PCM in a liquid state to yield a composite construction element in which the porosity of the construction element has been at least partially filled with the PCM. Such a composite construction element is preferably capable of increasing the thermal inertia of a building envelope constructed therefrom with little or no detrimental effects on properties of the construction elements.
E04C 1/41 - Building elements of block or other shape for the construction of parts of buildings built-up from parts of different materials, e.g. composed of layers of different materials or stones with filling material or with insulating inserts composed of insulating material and load-bearing concrete, stone or stone-like material
E04B 2/02 - Walls, e.g. partitions, for buildings; Wall construction with regard to insulation; Connections specially adapted to walls built-up from layers of building elements
E04C 2/284 - Building elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by specified materials composed of materials covered by two or more of groups , , , or of materials covered by one of these groups with a material not specified in one of these groups at least one of the materials being insulating
33.
DUAL AND TRIPLE HAPTEN CONJUGATES, COMPOSITIONS, PROCESSES FOR MAKING, AND METHODS OF TREATMENT THEREWITH
A conjugate having the formula TL-L-Hn, wherein TL is a targeting ligand for a target protein on the surface of a virus, a virus-infected cell, a cancer cell, an immune cell, or a fibroblast; L is a linker; H is a hapten; and n is an integer of 2 or greater. Compositions comprising the conjugate and methods of use are also provided.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Riley, Andrew
Van Rijn, Richard
Gutridge, Anna
Creed, Simone
Abstract
The present disclosure relates to compounds of formula I that can bind to one or more opioid receptors. In one aspect, the compounds described herein can bind to the kappa opioid receptor (KOR) and behave as an opioid receptor agonist. The ability of the compounds to bind to opioid receptors make them effective in the treatment or prevention of pain such as chronic pain.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
36.
DEVICES, SYSTEMS, AND METHODS FOR ANALYZING NANOPARTICLES AND MICROPARTICLES
Devices, systems, and methods for analyzing nanoparticles and microparticles. An exemplary device for analyzing microparticles and nanoparticles is disclosed herein, comprising an elongated capillary tube having a square cross-section, and a substrate configured to receive the elongated capillary tube thereon, wherein the elongated capillary tube is affixed to the substrate using an adhesive.
G01L 19/00 - MEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE - Details of, or accessories for, apparatus for measuring steady or quasi-steady pressure of a fluent medium insofar as such details or accessories are not special to particular types of pressure gauges
G01L 1/16 - Measuring force or stress, in general using properties of piezoelectric devices
37.
METHOD FOR GENERATING INFORMATION CODE USING FLUORESCENT SILK AND INFORMATION CODE GENERATED THEREBY
REPUBLIC OF KOREA(MANAGEMENT : RURAL DEVELOPMENT ADMINISTRATION) (Republic of Korea)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Kim, Seong Wan
Kim, Kee Young
Kim, Nam Sup
Kim, Seong Ryul
Kang, Sang Kug
Park, Jong Woo
Jung, Chan Young
Kim, Young L.
Leem, Jung Woo
Jeon, Hee-Jae
Park, Sang Mok
Ji, Yuhun
Abstract
The present invention relates to a method for generating an information code using fluorescent silk and an information code generated thereby. The method for generating an information code composed of a silk film according to the present invention comprises the steps of: producing a white silk film; generating a micro lattice pattern on the white silk film; and coating the white silk film with each of a plurality of fluorescent silk solutions at corresponding positions of the information code. The information code may be composed of white and colors corresponding to each of the plurality of fluorescent silk solutions.
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
38.
FLUORESCENT SILK INFORMATION CODE RECOGNITION METHOD AND DEVICE USING SAME
REPUBLIC OF KOREA(MANAGEMENT : RURAL DEVELOPMENT ADMINISTRATION) (Republic of Korea)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Kim, Seong Wan
Kim, Kee Young
Kim, Nam Sup
Kim, Seong Ryul
Kang, Sang Kug
Park, Jong Woo
Jung, Chan Young
Kim, Young L.
Leem, Jung Woo
Jeon, Hee-Jae
Park, Sang Mok
Ji, Yuhun
Abstract
The present invention relates to a fluorescent silk information code recognition method and a device using same. The fluorescent silk information code recognition method according to the present invention may comprise the steps of: scanning a fluorescent silk information code attached to or included in a product by using a camera; extracting a binary output key from the scanned fluorescent silk information code by using a trained artificial intelligence model; and authenticating the product by using the extracted binary output key.
G06K 7/14 - Methods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
G06K 19/10 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code using markings of different kinds in the same record carrier, e.g. one marking being sensed by optical and the other by magnetic means at least one kind of marking being used for authentication, e.g. of credit or identity cards
C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
H04L 9/06 - Arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
39.
NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES
bb]-pyridazine, substituted with one or more ring moieties, as well as conjugates and compositions comprising the same. Methods for treatment of kinase-associated diseases and disorders are also provided.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A versatile and efficient method is described for recovering a high-purity material (target) or multiple materials (targets) from a complex mixture in batch or continuous chromatography systems. If perfectly selective sorbents are available for the targets, constant-pattern batch capture methods in tandem or tandem carousel capture methods are preferred. If perfectly selective sorbents for the targets are unavailable, the batch capture, carousel capture, isocratic SMB, non- isocratic SMB, and isotachic displacement methods can be deployed in tandem or in parallel to produce high purity products with high yields and high productivity.
C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
C22B 3/42 - Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction
Radiation-tolerant, thin-film electrodes capable of use in potentiometric sensors and methods of using such electrodes. Such an electrode includes a substrate, an electrode disposed on the substrate, and a protective membrane covering the electrode, wherein the protective membrane is tolerant to gamma radiation such that the protective membrane is capable of tolerating a process of sterilization through gamma radiation.
This present disclosure teaches a method for treating or delaying castration-resistant prostate cancer (CRPC) comprising co-administering to a subject in need of relief from said cancer a therapeutically effective amount of a sterol-O-acyltransferase 1 (SOAT1) inhibitor together with a therapeutically effective amount of one or more androgen receptor inhibitors/antagonists. Examples of inhibitor/antagonist of androgen receptor and androgen biosynthesis include enzalutamide and abiraterone; and examples of SOAT1 inhibitors include avasimibe. Pharmaceutical compositions and methods of uses for the treatment of CRPCs are within the scope of this disclosure.
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N); Sulfinylamines (—N=SO); Sulfonylamines (—N=SO2)
Compounds, compositions and methods for inhibiting Syk from phosphorylating erythrocyte anion transporter band 3 and/or Syk tyrosine kinase. Further disclosed are methods of treating a subject for a disease involving the release of microvesicles from blood cells, including alpha-thalassemia or beta-thalassemia, sickle cell disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency or glutathione reductase deficiency.
FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (USA)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Curet, Oscar
Castillo, Luciano
Kazemi, Amirkhosro
Abstract
Apparatus and methods of harvesting energy are disclosed, the apparatus including: a) at least one cylindrical member; b) a mounting member; c) a securing member, wherein the securing member flexibly couples the cylindrical member to the mounting member; and d) a mechanical-to-electrical energy conversion member. Methods include : a) flexibly coupling at least one cylindrical member to a mounting member with a securing member; b) coupling a mechanical-to-electrical energy conversion member to the mounting member; c) placing the apparatus of the invention in a body of water with water current of a strength that is able to move the cylindrical member when the cylindrical member comes into contact with the water current; and d) generating electricity with the mechanical-to-electrical energy conversion member, wherein the movement of the cylindrical member in the water current provides necessary mechanical energy for the mechanical-to-electrical energy conversion member to generate electricity.
F03B 13/26 - Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using tide energy
F03B 13/18 - Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using wave energy using the relative movement between a wave-operated member and another member wherein the other member is fixed, at least at one point, with respect to the sea bed or shore
F03B 17/06 - Other machines or engines using liquid flow, e.g. of swinging-flap type
45.
SELECTIVE G PROTEIN-COUPLED RECEPTOR KINASE 5 INHIBITORS, COMPOSITIONS, AND METHODS OF USE
Highly selective and potent inhibitors of G protein-coupled receptor kinase 5 (GRK5), a pharmaceutical composition comprising same, and a method of use, such as in the treatment of heart disease or cancer.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
46.
COMMUNICATION AND POWERING SYSTEMS AND METHODS BETWEEN IMPLANTABLE AND WEARABLE DEVICES
A system includes a wearable device and an implantable device. The wearable device includes one or more signal transmitters and is configured to be positioned adjacent to or in contact with a human or animal body. The implantable device includes a signal receiver and is configured to be implanted onto or within the human or animal body. The one or more signal transmitters of the wearable device are configured to transmit the signals through the human or animal body to the signal receiver of the implanted device via a galvanic coupling operable using electro-quasistatic signal transmission. The system also includes a capacitive element positioned on an electrical current flow path of the galvanic coupling between at least one of the one or more signal transmitters and the signal receiver.
A method of overmolding an object of interest with a protective coating is disclosed, which includes receiving a mold having a top half and a bottom half dimensioned for an object of interest, placing the object of interest into the bottom half of the mold, spreading a layer or laying a sheet of a mixture cellulose nanofibril (CNF) and carboxymethyl cellulose (CMC) on to the object of interest, placing the top half of the mold onto the CNF/CMC layer, applying a predetermined pressure between the top and bottom halves of the mold, applying a predetermined amount of heat to the mold, to thereby molding the CNF/CMC mixture onto the object of interest, and removing the object of interest with the layer of CNF/CMC formed thereon from the mold after a predetermined amount of time.
D21J 3/00 - Manufacture of articles by pressing wet fibre pulp, or papier-mâché, between moulds
B65D 1/00 - Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations p
Electrochemical cells and electrolyte compositions therefor. Such an electrolyte composition includes lithium bifluorosulphonyl imide (LiFSI) dissolved in cyclopentyl methyl ether (CPME) solvent. The electrolyte composition has an anion-derived solvation structure that can form a lithium fluoride (LiF) layer on an anode of an electrochemical cell. The anion-derived solvation structure may reduce the covalent bond strength between the Li cations and FSI anions.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
H01M 10/0561 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes the electrolyte being constituted of inorganic materials only
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
C07K 7/04 - Linear peptides containing only normal peptide links
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The invention generally relates to polymer salts for improved drug delivery from amorphous solid dispersions. In certain aspects, the invention provides an amorphous solid dispersion (ASD) composition comprising an active pharmaceutical agent (API); and a polymer salt that enables dispersion of the API in an amorphous matrix.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
52.
ALPHA-METHYLENE AND AMINOMETHYL LACTONES AND LACTAMS FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
Clostridioides difficileClostridioides difficile, particularly the compounds α-methylene and α-aminomethyl lactones, lactams, iminolactones, and iminolactams, thiolactones, thionolactones, thiolactams, and thionolactams; pharmaceutical compositions; and methods for treating those infections.
FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (USA)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Curet, Oscar
Kazemi, Amirkhosro
Abstract
Systems and methods of coastal erosion protection are disclosed, the systems including at least one cylindrical member, wherein the at least one cylindrical member has a predetermined porosity and wherein the at least one cylindrical member has a predetermined submergence level in coastal water. The methods include identifying an area in need of coastal erosion protection; determining a strength of at least one erosion force upon the area; determining a coastal erosion risk level; positioning at least one cylindrical member in coastal water at a predetermined proximity to the area in need of coastal erosion protection; and securing the at least one cylindrical member to a sediment floor of the coastal water.
Peptidomimetic inhibitors of protein N-terminal methyltransferase 1, such as a compound with the following formula: a composition comprising same, and a method of use.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The forestry management system 100 includes a processor 102 which executes steps to input point cloud data into the forestry management system 100, segment an individual tree from the point cloud data using unsupervised, graph-based clustering, identify a metric of a tree using an algorithm, and determine a trunk location of the tree. The metrics include a height of the tree, a biomass of the tree, a health status of the tree, and/or a species of the tree. The metric also includes a stem location and/or a position of the tree. The algorithm has a canopy-to-root routing direction.
A method of reducing phenol-formaldehyde in a resin and producing laminates therefrom, including the steps of extracting eugenol from a biomass source, mixing the extracted eugenol with a first quantity of curing agent and a second quantity of water and a third quantity of MeOH solvent in the presence of a KOH catalyst to yield a first admixture, and heating the first admixture to yield a precook admixture. The method further includes adding urea and a crosslinking agent to the precook admixture, adding additional KOH to the precook admixture to yield a second admixture, and heating the second admixture to yield a resin product, wherein the resin product has replaced at least about a third of the phenol-formaldehyde with eugenol-based resin. Next, the method includes brushing resin product onto respective sheets of paper to yield respective sheets of impregnated paper, drying the respective sheets of impregnated paper to yield respective sheets of dried impregnated paper, stacking respective sheets of dried impregnated paper to yield a multiple-sheet laminate stack, and hot-pressing the multiple-sheet laminate stack to yield a cured multiple-sheet laminate.
C08G 8/04 - Condensation polymers of aldehydes or ketones with phenols only of aldehydes
C08G 8/08 - Condensation polymers of aldehydes or ketones with phenols only of aldehydes of formaldehyde, e.g. of formaldehyde formed in situ
C09D 161/04 - Condensation polymers of aldehydes or ketones with phenols only
C08G 8/10 - Condensation polymers of aldehydes or ketones with phenols only of aldehydes of formaldehyde, e.g. of formaldehyde formed in situ with phenol
A lignan separation and depolymerization assembly, including a soaking tank, an intake port operationally connected to the soaking tank, a high-pressure vapor explosion tank connected in fluidic communication with the soaking tank, and a knockout tank connected in fluidic communication with the high-pressure vapor explosion tank. The assembly further includes a high-pressure reactor vessel operationally connected to the high-pressure vapor explosion tank, at least one input port operationally connected to the high-pressure vessel, a filter press operationally connected to the high-pressure reactor vessel, a flash separator operationally connected to the filter press, a settling vessel operationally connected to the flash separator, and a dryer operationally connected to the filter press. The assembly also includes a liquid-liquid extraction vessel having an outlet port, an inlet port, and wherein the liquid-liquid extraction vessel is operationally connected to the settling vessel and a membrane separator operationally connected to the liquid-liquid extraction vessel, wherein the membrane separator both receives material from the liquid-liquid extraction vessel and supplies material to the liquid-liquid extraction vessel.
C07G 1/00 - Low-molecular-weight derivatives of lignin
B01D 29/01 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups ; Filtering elements therefor with flat filtering elements
C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
C08J 11/04 - Recovery or working-up of waste materials of polymers
59.
PRODUCTION OF RICE STRAW FIBER BOARD USING LIGNIN FROM CATALYTICALLY DEPOLYMERIZED RICE STRAW
2nnCHO, wherein n is between 0 and 6. The mixture of the resin cure package typically incudes an anhydride, and that anhydride is typically maleic anhydride. The mixture of the resin cure package may also include a polyamide epichlorohydrin as a crosslinking agent. The mixture of the resin cure package typically has a pH value of 6.5-7.5.
B32B 23/04 - Layered products essentially comprising cellulosic plastic substances comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance
B32B 23/02 - Layered products essentially comprising cellulosic plastic substances in the form of fibres or filaments
B32B 21/10 - Next to a fibrous or filamentary layer
B32B 21/02 - Layered products essentially comprising wood, e.g. wood board, veneer, wood particle board in the form of fibres, chips, or particles
60.
METHOD FOR MAKING COMPOSITE BOARD FROM METHANOL EXPLODED DEPOLYMERIZED LIGNIN AND COMPOSITE BOARD MADE OF THE SAME
A method of preparing a composite board, including soaking a first quantity of biomass fibers in methanol to yield a second quantity of methanol infused biomass fibers, placing the second quantity of methanol infused biomass fibers into a first pressure vessel to increase pressure therein, rapidly reducing pressure within the pressure vessel to yield a third quantity of methanol exploded biomass fibers, and placing the third quantity of methanol exploded biomass fibers into a second pressure vessel. The method further includes introducing methanol, hydrogen gas, nitrogen gas, and acid into the second pressure vessel to define a first admixture, heating the first admixture under increased pressure to yield a quantity of unpurified depolymerized lignin, mixing the quantity of unpurified depolymerized lignin with predetermined quantities of fiber, curing agent, paraffin wax, glyoxal, and dispersant to define a second admixture, and bonding the second admixture with cardboard to yield a formaldehydefree composite board.
A method of ascertaining identity, verification, or authentication of a product is disclosed which includes embedding a predetermined watermark on a host image, thereby generating an edible watermarked image, printing the watermarked image using edible ink on an attack-resistant edible substrate, affixing the printed substrate onto the product, providing a color reference chart along with the watermarked image, obtaining an image of the watermarked image from the product, establishing correspondence between the watermarked image and the color reference chart, correcting the obtained image based on the established correspondence, extracting the embedded predetermined watermark from the corrected watermarked image, and determining identity, verification, and authentication of the product by analyzing the extracted predetermined watermark of the watermarked image.
Compounds comprising a radical of a therapeutic agent conjugated to a radical of raltitrexed, 5-methyltetrahydrofolate (5-MTHF), an analog of raltitrexed, or an analog of 5-MTHF via a linker; compositions comprising same; and a method of immunomodulating Tregs.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
Method of assessing biomarkers of a cattle carcass indicative of a characteristic of the animal such as finishing regimen or ultimate pH of the muscles of the animal, and kits to facilitate performing the method.
Disclosed herein is a conductive composite material, comprising a pollen-based substrate layer, an elastomeric adhesive layer on top of the pollen-based substrate layer, a biocompatible polymer substrate layer on top of the elastomeric adhesive layer, and a metal layer on top of the biocompatible polymer substrate layer and a method of forming the same. Also disclosed herein is a stretchable biopolymer-based heating pad comprising a pollen-based substrate layer, a cured polymeric layer or a metal layer on top of the pollen-based substrate layer, where, when present, the cured polymeric layer comprises a cured polymeric material and a metal, an encapsulation coating comprising a polymeric material that encapsulates the cured polymeric layer or the metal layer, wherein the pollen-based substrate layer and the cured polymeric layer are patterned to provide a heating pad and the method of forming the same.
H01B 1/00 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors
A61K 50/00 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ECG) or for transcutaneous drug administration
A61F 7/08 - Warming pads, pans or mats; Hot-water bottles
65.
SUSTAINABLE BATTERY ELECTRODE WITH HIGH ACTIVE MATERIAL CONTENT
A cathode for a lithium-based battery may include a current collector and a cathode material. The cathode material may include an inactive material comprising a carbon conductor and vapor-phase oxidative chemical vapor deposited (oCVD) polymer binder, and an active material uniformly coated and conductively coupled together with the oCVD polymer.
H01M 4/13 - Electrodes for accumulators with non-aqueous electrolyte, e.g. for lithium-accumulators; Processes of manufacture thereof
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/50 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese
H01M 4/52 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
Examples of methods are described herein. In some examples, a method includes determining a first value based on a first neighborhood of a vertex of a three-dimensional (3D) mesh. In some examples, the first neighborhood has a first size based on a feature parameter. In some examples, the method includes determining a second value based on a second neighborhood of the vertex of the 3D mesh. In some examples, the second neighborhood has a second size that is different from the first size. In some examples, the method includes determining a depth value of the vertex based on the first value and the second value. In some examples, the method includes detecting whether a feature is present based on the depth value.
C05G 3/90 - Mixtures of one or more fertilisers with additives not having a specifically fertilising activity for affecting the nitrification of ammonium compounds or urea in the soil
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
70.
A FAST AND EFFICIENT PROCESS FOR THE PREPARATION OF N-RETINYLIDENE-N-RETINYLETHANOLAMINE (A2E)
A process for the preparation of high quality N-retinylidene- N-retinylethanolamine (A2E) using a continuous flow reaction system is described, wherein the process first provides a mixing point for one equivalent of ATR and about ten equivalents of ethanolamine, followed by later introduction of about twelve equivalents of acetic acid into the stream of the continuous reaction flow at about 25 °C using DMSO as the solvent. The products obtained by this process are also described. A rapid method to access the purity of a sample of A2E is described.
C07C 211/01 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
C07C 211/26 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
71.
METHODS FOR THERMAL OLIGOMERIZATION TO LIQUID FUEL RANGE PRODUCTS
21232626 olefins. The at least one porous support material is not a traditional catalyst and contains no additional catalytic metals, activators, promoters or acid sites.
C07C 2/04 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by addition between unsaturated hydrocarbons by oligomerisation of well-defined unsaturated hydrocarbons without ring formation
C10L 1/04 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons
72.
METHOD FOR OPERATING A FREQUENCY AGILE TUNABLE SELF-INJECTION LOCKING LASER SYSTEM AND SELF-INJECTION LOCKING LASER SYSTEM
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (Switzerland)
PURDUE RESEARCH FOUNDATION (USA)
Inventor
Kippenberg, Tobias
Bhave, Sunil
Tian, Hao
Riemensberger, Johann
Likhachev, Grigorii
Siddharth, Anat
Abstract
The invention relates to a Method for operating a frequency agile tunable self-injection locking laser system being formed by a laser device coupled to at least one optical resonator, wherein a diode current of a laser diode of the laser device is controllable and wherein the optical resonator is controllable by controlling a piezo or an electro-optical actuator configured to apply a variation of the refractive index of the resonator material through mechanical stress or an electric displacement field, respectively, at least partially onto the at least one optical resonator depending on an actuation voltage, inducing a change in the effective optical path length of the at least one optical resonator, comprising the steps of: - Selecting a self-injection locking range among a plurality of self-injection locking ranges by varying a laser diode current and monitoring self-injection locking ranges, wherein self-injection locking ranges corresponding to current ranges in which self-injection locking occurs, wherein the self-injection locking corresponds to an optical feedback phase for back-reflected light from the optical resonator into the laser device, - setting the diode current from the current range of the selected self-injection locking mode; - determining a maximum tuning range of the actuation voltage in which self-injection locking is maintained; - operating the laser system with actuation voltages in a range depending on the determined tuning range.
H01S 5/062 - Arrangements for controlling the laser output parameters, e.g. by operating on the active medium by varying the potential of the electrodes
H01S 5/02325 - Mechanically integrated components on mount members or optical micro-benches
H01S 5/068 - Stabilisation of laser output parameters
H01S 5/06 - Arrangements for controlling the laser output parameters, e.g. by operating on the active medium
73.
HETERODIMERIC BENZALDEHYDE SYNTHASE, METHODS OF PRODUCING, AND USES THEREOF
The disclosure generally relates to production of natural or semi-natural benzaldehyde and its derivatives using a heterodimeric benzaldehyde synthase comprising a benzaldehyde synthase alpha (BS ) subunit and a benzaldehyde synthase beta (BS ) subunit, nucleic acids encoding the subunits, an engineered heterodimeric benzaldehyde synthase, transgenic plants that produce the heterodimeric benzaldehyde synthases hereof, and resulting products containing natural or seminatural benzaldehyde.
Intraocular pressure (IOP) tonometers, systems including IOP tonometers, methods of fabricating IOP tonometers, and methods for using systems to monitor IOP in a subject. The IOP tonometers include a contact lens configured to be located and retained on a user's eye, and a corneal sensor having a circular trace located proximate an outer peripheral edge of the contact lens so as to leave an unobstructed area at a center region of the contact lens. The corneal sensor produces a detectable shift in resonance frequency in response to a change in IOP of the user's eye, which is wirelessly delectable by a receiving antenna. The IOP tonometer is fabricated by depositing one or more layers of the circular trace onto a temporary substrate and then transferring the circular trace onto the outer surface of the contact lens.
A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
75.
METHOD AND SYSTEM FOR A FLOW-ISOLATED VALVE ARRANGEMENT AND A THREE-CHAMBER CYLINDER HYDRAULIC ARCHITECTURE
A hydraulic circuit is disclosed which includes one or more i) linear; or ii) rotary hydraulic actuator, wherein total number of cylinder chambers is N, M pressure rails, a valve arrangement, including M hydraulic rail ports each coupled to a pressure rail, N hydraulic chamber ports each coupled to a chamber of one or more actuators, N proportional valves each corresponding to one of the N hydraulic chamber ports, X sets of on-off valves and check valves coupling two or more hydraulic rail ports to each of supply sides of each of the N proportional valves, and Y sets of on-off valves and check valves coupling two or more hydraulic rail ports to each of return sides of each of the N proportional valves, and a controller configured to in real- time operate the N proportional valves and the associated on-off valves to achieve one or more desired functional parameters.
F15B 11/036 - Systems essentially incorporating special features for controlling the speed or the actuating force or speed of an output member for controlling the actuating force by means of servomotors having a plurality of working chambers
F15B 3/00 - Intensifiers or fluid-pressure converters, e.g. pressure exchangers; Conveying pressure from one fluid system to another, without contact between the fluids
76.
NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING
An abuse-deterrent formulation comprising an abuse-prone drug encapsulated in nanoparticles, a gel-forming polymer, and pharmaceutically acceptable excipients; method of use; and method of making.
Methods of detecting diagnostic indicators of a fracture-related infection (FRI) in a patient's biological sample are provided along with methods of treating the identified patients having an FRI.
G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
In some examples, a computing device can include a processor resource and a non-transitory memory resource storing machine-readable instructions stored thereon that, when executed, cause the processor resource to identify a base resolution of a captured image having a base image quality, perform, via an individual neural network, neural network calculations on the captured image to form an enhanced image having an resolution that is higher than the base resolution and image quality that is higher than the base image quality.
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/26 - Segmentation of patterns in the image field; Cutting or merging of image elements to establish the pattern region, e.g. clustering-based techniques; Detection of occlusion
INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (Republic of Korea)
Inventor
Lee, Chi Hwan
Paulus, Yannis Mantas
Kim, Dong Rip
Abstract
Ocular drug delivery device and related methods. The ocular drug delivery device includes a contact lens having a curvature configured to fit a cornea of an eye, an array of silicon nanoneedles attached to and protruding from a surface of the contact lens, and a therapeutic drug cargo loaded onto individual nanoneedles of the array of silicon nanoneedles. A method of releasing a therapeutic drug cargo to an eye with the ocular drug delivery device includes applying the ocular drug delivery device to the eye such that the surface of the contact lens contacts the cornea of the eye and individual nanoneedles of the array of nanoneedles are inserted into the cornea. The contact lens dissolves while leaving the individual nanoneedles inserted in the cornea. The individual nanoneedles degrade in the cornea over time causing release of the therapeutic drug cargo loaded thereon.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
A61F 9/00 - Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The invention generally relates to methods, reagents, and substrates for detecting target analytes, especially spectroscopic techniques such as laser-induced breakdown spectroscopy (LIBS) for use in food authentication and molecular detection (e.g., when combined with later flow immunoassays (LFIA).
G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
81.
FLEXIBLE MICRONEEDLE ARRAY PATCH FOR CHRONIC WOUND OXYGENATION AND BIOFILM ERADICATION
A medical patch may include a flexible substrate and a plurality of water-soluble microneedles extending from a surface of the substrate. The water-soluble microneedles may include polyvinylpyrrolidone (PVP) and calcium peroxide (CPO). Application of the medical patch to a wound causes the PVP to dissolve and the CPO to interact with the water and form hydrogen peroxide and oxygen.
A computer-implemented method of operating on a program is disclosed which includes executing at least one instruction towards method of operating a program, the execution includes receiving request for input data associated with at least one dataset; at run time determining if the input data associated with the at least one dataset is resident on memory of one or more processors of a second class (Class2 Processors), if the associated data is resident on the memory of at least one or more processors of a first class (Class2 Processors) and not resident on the memory of the Class2 Processors, i) retrieving only the associated input data from the memory of the Classi Processors, ii) copying the associated input data onto the memory of the Class2 Processors, iii) using the retrieved input data in the execution of the at last one instruction, and iv) generating output data.
Paint compositions and paint coatings for radiative cooling, as well as related methods of manufacturing and use of such paint compositions. A composition for paint to be used in radiative cooling, in a wet coating phase, includes nanoplatelets of hexagonal boron nitride, an acrylic binder, and a solvent. A coating of a dried paint on a surface to be cooled by radiative cooling includes nanoplatelets of hexagonal boron nitride and an acrylic binder. A method of manufacturing the composition for paint in the wet paint phase includes forming a first mixture by adding the nanoplatelets of hexagonal boron nitride to the solvent, uniformly distributing the nanoplatelets in the first mixture, and forming a second mixture by adding the acrylic binder to the first mixture.
C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
C09D 133/00 - Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, a; Coating compositions based on derivatives of such polymers
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 47/16 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen
86.
PLANT-BASED WALL MATERIALS AND EMULSIFIERS AND THE USES AND METHODS OF MANUFACTURE THEREOF
Wall materials and emulsifiers that comprise a material separated or isolated from a specific genotype of cereals, compositions, products, and encapsulation and/or emulsification methods.
METHODS AND COMPOSITIONS FOR VACCINATION AGAINST HETEROSUBTYPIC INFLUENZA VIRUSES USING AN ADENOVIRAL VECTOR LEADING TO ENHANCED T CELL RESPONSE THROUGH AUTOPHAGY
An adenoviral vector with E1 and E3 regions removed and expressing the nucleoprotein or other immunogenic domain(s) of an influenza virus with or without the presence of the Autophagy-Inducing Peptide C5 (AIP-C5) from the CFP10 protein of Mycobacterium tuberculosis, compositions comprising same, and methods of use for general vaccination against heterosubtypic influenza viruses.
An ultra-low-power wireless impedance measurement system is provided having a sensor group with a piezoelectric sensor, a temperature sensor, an impedance analyzer and a wireless transceiver is to transmit associated data via wireless transmission. Processed temperature and impedance data are transmitted to a server, whereby the processed temperature and impedance data are conveyed to a user via a website.
G01R 27/00 - Arrangements for measuring resistance, reactance, impedance, or electric characteristics derived therefrom
G01R 31/00 - Arrangements for testing electric properties; Arrangements for locating electric faults; Arrangements for electrical testing characterised by what is being tested not provided for elsewhere
89.
NANOCONSTRUCTS AND NANOPARTICLE-MEDIATED DELIVERY OF IMMUNOGENIC CELL DEATH INDUCERS FOR ENHANCING CANCER IMMUNOTHERAPY
Nanoconstructs and compositions comprising a nanoparticle coated with an immunoadjuvant (e.g, ATP) and comprising one or more therapeutic agents (e.g, ICD inducer) encapsulated therein; and methods for treating cancer in a subject using such nanoconstructs and compositions, as well as combination immunotherapies.
Methods of treating severe and uncomplicated malaria comprising administering an isoform of artemisinin, a hydrophobic amine, and a spleen tyrosine kinase (Syk) inhibitor. Further provided is a unitary, oral dosage form comprising an isoform of artemisinin, a hydrophobic amine, and a Syk inhibitor; and a kit comprising multiple unitary, oral dosage forms and instructions for administration.
C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
21212 alkanes with a bifunctional catalyst comprising platinum (Pt) or palladium (Pd) and at least one other metal (M) to provide an alloy (Pt-M or Pd-M) containing at least 0.1 wt% of the platinum (Pt) or palladium (Pd), based on a total weight of the catalyst; a silica or alumina support; and an acidic zeolite, at a temperature of about 350°C to 700°C to provide a liquid product having a boiling point of 38°C to 205 °C.
A composition comprising (i) a resistant starch, (ii) resistant dextrin/ maltodextrin, a resistant non-starch α-linked glucan, or both, (iii) a cereal bran, which is optionally stabilized, and (iv) inulin, a fructooligosaccharide, or both; an ingestible formulation comprising the composition; and a method of improving gastrointestinal health in a human with a condition, disease, or disorder, which method comprises administering to the human the composition or the ingestible formulation.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Various aspects disclosed relate to a method of preparing a substantially sequence-uniform aliphatic copolyester. The method includes continuously contacting at least, a first monomer and a second monomer with an initiator and a catalyst to initiate ring-opening copolymerization of the first monomer and the second monomer. In the method the first monomer and the second monomer are contacted with the initiator and catalyst at a feed rate that is slower than a polymerization rate of the first monomer and the second monomer.
In one example in accordance with the present disclosure, an electronic device is described. An example electronic device includes a processor and memory storing executable instructions that when executed cause the processor to generate multiple synthetic images of an object based on defined object parameters and randomized visual parameters. The instructions also cause the processor to generate annotations of the object in multiple synthetic images based on the defined object parameters and the randomized visual parameters. The instructions further cause the processor to train a machine-learning (ML) model for detecting the object using the multiple synthetic images and annotations.
A tunable hyperspectral-polarimetric filter system includes a first polarizer, a crystal filter and a second polarizer. The first polarizer is configured to transmit light in a first direction of linear polarization. The polarization selection may be substantially the same for all wavelengths at a spectral range of interest. The crystal filter, may be parallelly and coaxially disposed after the first polarizer. The crystal filter is configured to rotates the first direction of linear polarization for light transmitted by the first polarizer, wherein rotation angles differ for different wavelengths at the spectral range of interest. The second polarizer may be parallelly and coaxially disposed after the crystal filter. The second polarizer may substantially transmit a second direction of linear polarization of the light transmitted by the crystal filter. The first polarizer and/or the second polarizer are rotatable to tune for different transmission spectra for spectral and polarimetric imaging resolution.
In an example implementation according to aspects of the present disclosure, an image is divided into a grid of grid regions. An aesthetic score map is generated which includes an aesthetic score for each of the grid regions using a machine learning model. A plurality of candidate image re-compositions is identified based on a plurality of combinations of the grid regions. A candidate image score for each of the candidate image re-compositions is determined using the aesthetic score map for each of the plurality of combinations of the grid regions. An image re-composition is selected from the candidate image re-compositions based on each of the candidate image scores.
G06V 10/26 - Segmentation of patterns in the image field; Cutting or merging of image elements to establish the pattern region, e.g. clustering-based techniques; Detection of occlusion
G06N 3/04 - Architecture, e.g. interconnection topology
The invention generally relates to systems and methods for focusing ions using counter flows of opposite or like charged ions. In certain embodiments, oppositely charged ions are introduced in a counter flow to a target ion beam within an atmospheric ion guide.
A conjugate of formula EVTsmL-L-AMRL, wherein EVTsmL is an enveloped virus-targeting, small molecule ligand, AMRL is an activated macrophage-recruiting ligand, and L is a linker that is covalently bound to EVTsmL and AMRL; a composition comprising the same; and a method of using the conjugate or composition to treat (therapeutically or prophylactically) a viral infection.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
C07D 309/16 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
A conjugate of formula (I) FRTL-BBMecL-AA or (II) FRTL-Alb-BBMecL-AA, wherein FRTL is a folate receptor-targeting ligand, BBMecL is a brush border membrane (BBM) enzyme-cleavable linker, Alb is an albumin-binder moiety, and AA is an active agent; composition comprising same; and method of imaging and/or treating a tumor.
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (Canada)
Inventor
Jones, Thomas
Peroulis, Dimitrios
Fisher, Alden
Barlage, Douglas
Abstract
A waveguide assembly integrated with a semiconductor wafer is provided. The waveguide assembly includes a waveguide channel defined by internal walls of the wafer lined with a metallic layer, and having at least one port for transmission of the RF signal into or out of the waveguide channel. The waveguide assembly also includes a semiconductor obstacle 5 member disposed in the waveguide channel. The waveguide assembly may be fabricated using etching and deposition processes for semiconductor devices. In use, selectively varying either one or both of frequency or power level of electromagnetic radiation applied to the obstacle member varies electrical conductance of the obstacle member, and thereby varies the electrical impedance of the obstacle member to transmission of the RF signal 10 through the waveguide channel. The waveguide assembly may be used for switching, attenuating, routing, filtering, and transforming the RF signal.
H01L 27/00 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate
B81B 7/02 - Microstructural systems containing distinct electrical or optical devices of particular relevance for their function, e.g. microelectro-mechanical systems (MEMS)
G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
patents
